Study to Investigate Safety, Absorption, Elimination, and Drug Effect of BAY2327949 in Participants With Different Renal Function Status

Inclusion Criteria: * Participant must be ≥18 years of age * The study enrolls healthy participants and participants at different stages of renal impairment (mild to severe renal impairment). * Race: White * BMI (body mass index): above or equal 18.5 and below or equal 35 kg/m\*2 at the first screening visit. * Male or female. * Participants with renal impairment must have an eGFR (estimated glomerular filtration rate) \<90 mL/min/1.73 m\*2 determined from serum creatinine 21-3 days prior to dosing using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation (eGFR has to be repeated if screening period \>10 days before dosing). Stable renal function, e.g. a serum creatinine value determined at least 3 months before the pre-study visit should not vary by more than 25% from the serum creatinine value determined at the pre-study visit confirmed by nephrologist or general practitioner the patient is under care. Exclusion Criteria: * Clinically relevant findings in the physical examination affecting the objectives of the study. * Systemic use of the following co-medications from 2 weeks before administration until end of follow-up: * Moderate and strong inhibitors of CYP3A; * Moderate and strong CYP3A inducers; * Moderate and strong inhibitors of P-gp transport; * UDP-glucuronosyltransferase (UGT) inhibitors probenecid and valproic acid. * Regular daily consumption of more than 10 cigarettes. * Acute renal failure. * Active nephritis. * Impairment of any other major organ system other than the kidney. * Change in chronic medications for renal disease (or its consequences) less than 4 weeks prior to dosing.